1998
DOI: 10.1159/000022448
|View full text |Cite
|
Sign up to set email alerts
|

The Beneficial Effect of a β-D-Xyloside, Iliparcil, in the Prevention of Postthrombolytic Rethrombosis in the Rat

Abstract: The effect of Iliparcil, a new orally active β-D-xyloside venous antithrombotic, was studied on the rethrombosis following thrombolytic therapy in rats, using a modified Umetsu model. The drug was administered by oral route prior to thrombolytic therapy, which consisted of administering a combination of heparin and urokinase (H/U) at 37.5 and 70,000 IU/kg, respectively. Time to reocclusion increased from 3.9 min with saline to 10.5 min following H/U injection. When Iliparcil (30 mg/kg, oral route) was administ… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
8
0

Year Published

2003
2003
2021
2021

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(8 citation statements)
references
References 17 publications
0
8
0
Order By: Relevance
“…In the following report, the xyloside approach has been further investigated with the novel β ‐D‐thioxyloside odiparcil. Odiparcil is an orally active antithrombotic agent currently in clinical studies, and is the result of a medicinal chemistry effort, based on the learnings from predecessor molecules [13,18], aimed at optimizing the antithrombotic, clinical pharmacokinetic (PK), and overall developability profile of xylosides.…”
Section: Introductionmentioning
confidence: 99%
“…In the following report, the xyloside approach has been further investigated with the novel β ‐D‐thioxyloside odiparcil. Odiparcil is an orally active antithrombotic agent currently in clinical studies, and is the result of a medicinal chemistry effort, based on the learnings from predecessor molecules [13,18], aimed at optimizing the antithrombotic, clinical pharmacokinetic (PK), and overall developability profile of xylosides.…”
Section: Introductionmentioning
confidence: 99%
“…Odiparcil (SB‐424323; Figure 1) is a novel orally active β‐ d ‐thioxyloside antithrombotic compound chemically similar to its predecessor congeners naroparcil 15 , 16 and iliparcil 17 . In a recent phase IIa study TEMPEST (ThromboEMbolism Prevention Efficacy and Safety Trial), odiparcil 125 mg or 500 mg twice daily was administered to patients (n = 225) undergoing total hip replacement surgery.…”
mentioning
confidence: 99%
“…It is used in nearly every current acute stroke study in the United States as a measure of the initial and final neurological deficit. The MBI is a commonly used scale that measures disability or dependence in activities of daily living in stroke patients (Engberg et al, 1995;Sulter et al, 1999;de Haan et al, 1993).…”
Section: Discussionmentioning
confidence: 99%
“…Ligustici radix decreases ischemic necrosis rate by promoting microcirculation, preventing clot formation, and reducing exudation and hemorrhage (Chen, 1993). Beta-D-xyloside in Cimicifugae rhizoma has proven to increase the re-occlusion time after thrombolytic therapy in rats (Chicaud et al, 1998;Koeda et al, 1995). Angelicae radix has anti-platelet aggregation effect (Shimizu et al, 1991).…”
Section: Discussionmentioning
confidence: 99%